PCSK9 Inhibition: From Current Advances to Evolving Future

PCSK9 Inhibition: From Current Advances to Evolving Future

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a secretory serine protease synthesized primarily by the liver. It mainly promotes the degradation of low-density lipoprotein receptor (LDL-R) by binding LDL-R, reducing low-density lipoprotein cholesterol (LDL-C) clearance. In addition to reg...

Full description

Bibliographic Details
Main Authors: Chunping Liu, Jing Chen, Huiqi Chen, Tong Zhang, Dongyue He, Qiyuan Luo, Jiaxin Chi, Zebin Hong, Yizhong Liao, Shihui Zhang, Qizhe Wu, Huan Cen, Guangzhong Chen, Jinxin Li, Lei Wang
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cells
Subjects:
cardiovascular disease
PCSK9 inhibitors
clinical applications
security
research status
Online Access:https://www.mdpi.com/2073-4409/11/19/2972

Internet

https://www.mdpi.com/2073-4409/11/19/2972

Similar Items